The U.S. Food and Drug Administration secured a court order barring a New Jersey pharmaceutical company from distributing more than 50 unapproved cough and cold medicines, the Associated Press reported Friday.
East Windsor, N.J.-based Advent Pharmaceuticals continued to market the unapproved products despite prior warnings, and failed to correct manufacturing problems identified by FDA inspectors, the AP said. Advent products and those from its subsidiary, Neilgen Pharmaceuticals, covered in the order include BP Allergy Junior Suspension, RE All 12 Suspension, and many others, the AP reported. Neilgen, based in Westminster, Md., also does business as Unigen Pharmaceuticals, the FDA said.
Consumers were urged to discontinue use of the products and to consult with a physician for alternatives. Company officials did not immediately respond to calls for comment Friday afternoon, the AP said.
A complete list of the unapproved cold medications is available on the FDA Web site at www.fda.gov/bbs/topics/NEWS/2009/NEW01995.html.